ECSP21062210A - Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias - Google Patents
Derivados de aminoácidos para el tratamiento de enfermedades inflamatoriasInfo
- Publication number
- ECSP21062210A ECSP21062210A ECSENADI202162210A ECDI202162210A ECSP21062210A EC SP21062210 A ECSP21062210 A EC SP21062210A EC SENADI202162210 A ECSENADI202162210 A EC SENADI202162210A EC DI202162210 A ECDI202162210 A EC DI202162210A EC SP21062210 A ECSP21062210 A EC SP21062210A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- amino acid
- acid derivatives
- inflammatory diseases
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación proporciona ciertos derivados de aminoácidos que inhiben la activación de NF-kB y, por lo tanto, son útiles para el tratamiento de enfermedades inflamatorias. También se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962795549P | 2019-01-22 | 2019-01-22 | |
US201962871951P | 2019-07-09 | 2019-07-09 | |
PCT/US2020/014636 WO2020154420A2 (en) | 2019-01-22 | 2020-01-22 | Amino acid derivatives for the treatment of inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21062210A true ECSP21062210A (es) | 2022-06-30 |
Family
ID=69726748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202162210A ECSP21062210A (es) | 2019-01-22 | 2021-08-20 | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220081415A1 (es) |
EP (1) | EP3924349A2 (es) |
JP (1) | JP2022524571A (es) |
KR (1) | KR20210141930A (es) |
CN (1) | CN113614074A (es) |
AU (1) | AU2020211980A1 (es) |
BR (1) | BR112021014372A2 (es) |
CA (1) | CA3127246A1 (es) |
CL (1) | CL2021001944A1 (es) |
CO (1) | CO2021010931A2 (es) |
EC (1) | ECSP21062210A (es) |
IL (1) | IL284980A (es) |
MA (1) | MA54940A (es) |
MX (1) | MX2021008748A (es) |
SG (1) | SG11202107977TA (es) |
WO (1) | WO2020154420A2 (es) |
ZA (1) | ZA202105229B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210113184A (ko) | 2018-11-30 | 2021-09-15 | 코멧 테라퓨틱스, 인코포레이티드 | 사이클릭 판테테인 유도체 및 이들의 용도 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6218390B1 (en) * | 1998-12-17 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Morpholinone and morpholine derivatives and uses thereof |
EP2424850A1 (en) * | 2009-05-01 | 2012-03-07 | Profectus Biosciences, Inc. | Benzamide and naphthamide derivatives inhibiting nuclear factor- kap pa (b) - (nf-kb) |
-
2020
- 2020-01-22 CN CN202080021880.4A patent/CN113614074A/zh active Pending
- 2020-01-22 US US17/424,455 patent/US20220081415A1/en active Pending
- 2020-01-22 SG SG11202107977TA patent/SG11202107977TA/en unknown
- 2020-01-22 CA CA3127246A patent/CA3127246A1/en active Pending
- 2020-01-22 BR BR112021014372-6A patent/BR112021014372A2/pt unknown
- 2020-01-22 MA MA054940A patent/MA54940A/fr unknown
- 2020-01-22 JP JP2021543302A patent/JP2022524571A/ja active Pending
- 2020-01-22 KR KR1020217026302A patent/KR20210141930A/ko unknown
- 2020-01-22 WO PCT/US2020/014636 patent/WO2020154420A2/en unknown
- 2020-01-22 EP EP20708296.7A patent/EP3924349A2/en active Pending
- 2020-01-22 MX MX2021008748A patent/MX2021008748A/es unknown
- 2020-01-22 AU AU2020211980A patent/AU2020211980A1/en active Pending
-
2021
- 2021-07-20 IL IL284980A patent/IL284980A/en unknown
- 2021-07-22 CL CL2021001944A patent/CL2021001944A1/es unknown
- 2021-07-23 ZA ZA2021/05229A patent/ZA202105229B/en unknown
- 2021-08-19 CO CONC2021/0010931A patent/CO2021010931A2/es unknown
- 2021-08-20 EC ECSENADI202162210A patent/ECSP21062210A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210141930A (ko) | 2021-11-23 |
CO2021010931A2 (es) | 2022-01-17 |
IL284980A (en) | 2021-09-30 |
SG11202107977TA (en) | 2021-08-30 |
US20220081415A1 (en) | 2022-03-17 |
JP2022524571A (ja) | 2022-05-09 |
CN113614074A (zh) | 2021-11-05 |
CL2021001944A1 (es) | 2022-05-06 |
WO2020154420A3 (en) | 2020-09-10 |
WO2020154420A2 (en) | 2020-07-30 |
AU2020211980A1 (en) | 2021-08-19 |
ZA202105229B (en) | 2022-12-21 |
WO2020154420A4 (en) | 2020-11-12 |
EP3924349A2 (en) | 2021-12-22 |
BR112021014372A2 (pt) | 2021-09-28 |
CA3127246A1 (en) | 2020-07-30 |
MA54940A (fr) | 2021-12-22 |
MX2021008748A (es) | 2022-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
NI201900041A (es) | 1, 2, 4-triazolonas 2, 4, 5-trisustituidas | |
UY37656A (es) | Compuestos que inhiben la proteína mcl-1 | |
CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
CL2019001092A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas. | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
CL2021003568A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198) | |
DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
ECSP21013743A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CL2022003703A1 (es) | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos | |
AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
ECSP21062210A (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
CL2021000618A1 (es) | Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo | |
CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 |